FDA approves combo for ESR1-mutated breast cancer - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

  • By

  • Kathryn Wighton

  • September 21, 2026

  • 2 min

Share

Original Source(s)

FDA approves combo for ESR1-mutated breast cancer

  • by Kathryn Wighton

  • September 21, 2026

Related Content

Comprehensive Cancer Care for the Doral Community

Baptist Health Cancer Care is now serving patients in Doral with a comprehensive, community-based approach to oncology care designed to make treatment more convenient and accessible for both patients and referring physicians.

  • by

  • June 2, 2026

  • 2 min
Medical debt linked to higher late-stage cancer rates

Lung cancer showed the strongest absolute association, while prostate and breast cancer findings diverged from the broader pattern.

Social vulnerability may contribute to disparities in ovarian cancer survival

Neighborhood vulnerability was associated with poorer survival among women with epithelial ovarian cancer, with a stronger association among Black women.